Yahoo is using AI to generate takeaways from this article.

The FDA has fast-tracked six therapies since December 2025 through its priority review and National Priority Voucher programs, including the first approval issued under the agency's new pilot pathway.

The U.

GAITHERSBURG, Md.

(RTTNews) - ScinoPharm Taiwan (TWSE: 1789) today announced that the U.

Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D in children aged one and older diagnosed with stage 2 T1DTzield slows disease progression by protecting the insulin-secreting beta cells of the pancreasThe priority review is based on interim results from the PETITE-T1D phase 4 study Paris, January 5, 2026.

All information and data in this article is solely for informational purposes.

CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.